Menu Search
Equities

Venus Medtech Hangzhou Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2500:HKG

Venus Medtech Hangzhou Inc

Actions
Health CareMedical Equipment and Services
  • Price (HKD)2.79
  • Today's Change-0.03 / -1.06%
  • Shares traded774.50k
  • 1 Year change-50.36%
  • Beta0.9765
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Venus Medtech Hangzhou Inc had revenues fall -4.18% from 491.37m to 470.83m, though the company grew net income from a loss of 703.75m to a smaller loss of 714.31m.
Gross margin75.83%
Net profit margin-150.57%
Operating margin-151.18%
Return on assets-18.34%
Return on equity-26.82%
Return on investment-21.01%
More ▼

Cash flow in CNYView more

In 2024, cash reserves at Venus Medtech Hangzhou Inc fell by 476.36m. However, the company earned 23.74m from its operations for a Cash Flow Margin of 5.04%. In addition the company used 19.90m on investing activities and also paid 487.34m in financing cash flows.
Cash flow per share-1.40
Price/Cash flow per share--
Book value per share5.30
Tangible book value per share1.57
More ▼

Balance sheet in CNYView more

Venus Medtech Hangzhou Inc has a Debt to Total Capital ratio of 19.28%, a higher figure than the previous year's 12.24%.
Current ratio1.82
Quick ratio1.56
Total debt/total equity0.2389
Total debt/total capital0.1928
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.